Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22743961 | 0.90 | OPRL1 (0.34) | OPRL1PDK2FNTAFNTB | |
| SCHEMBL26833427 | 0.90 | OPRL1 (0.34) | OPRL1PDK2FNTAFNTB | |
| SCHEMBL23869928 | 0.90 | OPRL1 (0.34) | OPRL1PDK2FNTAFNTB | |
| SCHEMBL2148122 | 0.79 | OPRL1 (0.42) | OPRL1SIGMAR1PDK2NR3C1FNTA | |
| SCHEMBL23364947 | 0.76 | CYP1A2 (0.39) | OPRL1SIGMAR1NR3C1FNTAFNTB | |
| SCHEMBL15894663 | 0.76 | CYP1A2 (0.39) | OPRL1SIGMAR1NR3C1FNTAFNTB | |
| SCHEMBL26836231 | 0.76 | OPRL1 (0.34) | OPRL1PDK2 | |
| SCHEMBL15469382 | 0.74 | CYP3A4 (0.34) | OPRL1SIGMAR1PDK2FNTAFNTB | |
| SCHEMBL23869975 | 0.73 | DRD2 (0.33) | OPRL1 | |
| SCHEMBL24125123 | 0.72 | KDM1A (0.36) | OPRL1SIGMAR1NR3C1F2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | OPRL1 3884/4885SIGMAR1 4693/4885PDK2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.